Mesoblast

Mesoblast EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Mesoblast (MSB.AX) as of Nov 19, 2026 is 16.09 %. In the previous year, Year-over-Year EBITDA Growth was 24.49 % — a change of -34.30% (lower).

EBITDA Growth YoY

16.09 %

YoY

-34.30%

Last updated:

Year-over-Year EBITDA Growth of Mesoblast is 2026 16.09 % . Year-over-Year EBITDA Growth of Mesoblast was 2025 24.49 % . It decreases by -34.30% lower compared to the previous year.

The Mesoblast EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
-3.99 USD
Jan 1, 2020
6.77 USD
Jan 1, 2021
-46.59 USD
Jan 1, 2022
26.49 USD
Jan 1, 2023
14.26 USD
Jan 1, 2024
-21.92 USD
Jan 1, 2025
24.49 USD
Jan 1, 2026
16.09 USD
The Mesoblast EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
16.09 %-34.30%
24.49 %-211.73%
-21.92 %-253.64%
14.26 %-46.15%
26.49 %-156.86%
-46.59 %-788.31%
6.77 %-269.49%
-3.99 %-125.11%
15.90 %-126.02%
-61.11 %-220.51%
50.71 %-189.49%
-56.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Year-over-Year EBITDA Growth of Mesoblast is 16.09 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Mesoblast since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Mesoblast

All Key Metrics — Mesoblast